Beam Therapeutics (BEAM)
(Delayed Data from NSDQ)
$21.26 USD
-1.28 (-5.68%)
Updated May 10, 2024 04:00 PM ET
After-Market: $21.27 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Beam Therapeutics Inc. [BEAM]
Reports for Purchase
Showing records 61 - 80 ( 113 total )
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2021 Abstract Roundup For Covered CompaniesThis report contains brief updates on the following: ACET, ALPN, ANAB, BCEL, BEAM, CDAK, CTMX, FATE, IGMS, MRSN. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
BEAM Delivers Sweet GSDIa Base Editing Data and a Knockout Deal with SANA
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
SITC 2021 Abstract Titles for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Beam Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Q2:21: Will There Be a Gold in the BEAM Going into Year End?
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D